|Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …|
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
|Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials|
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
|COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study|
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
|Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer|
L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ...
JAMA oncology 4 (3), 351-357, 2018
|Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study|
L Crinò, E Dansin, P Garrido, F Griesinger, J Laskin, N Pavlakis, ...
The lancet oncology 11 (8), 733-740, 2010
|Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non–small cell lung cancer: the SELECT-1 randomized …|
PA Jänne, MM Van Den Heuvel, F Barlesi, M Cobo, J Mazieres, L Crinò, ...
Jama 317 (18), 1844-1853, 2017
|Patient involvement in clinical research: why, when, and how|
JA Sacristán, A Aguarón, C Avendaño-Solá, P Garrido, J Carrión, ...
Patient preference and adherence 10, 631, 2016
|Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the …|
R Rosell, R Gervais, A Vergnenegre, B Massuti, E Felip, F Cardenal, ...
Journal of clinical oncology 29 (15_suppl), 7503-7503, 2011
|Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus|
G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ...
Annals of Oncology 31 (10), 1320-1335, 2020
|The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC|
C Manegold, AMC Dingemans, JE Gray, K Nakagawa, M Nicolson, ...
Journal of Thoracic Oncology 12 (2), 194-207, 2017
|Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial|
M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ...
Annals of Oncology 27 (3), 417-423, 2016
|Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study.|
J Feliu, M Gonzalez-Baron, A Berrocal, A Artal, A Ordonez, P Garrido, ...
American journal of clinical oncology 15 (5), 436-440, 1992
|Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis|
M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ...
The Lancet Respiratory Medicine 6 (10), 771-781, 2018
|Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study|
K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ...
Journal of Clinical Oncology 39 (30), 3391-3402, 2021
|Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: the Spanish Lung …|
P Garrido, JL González-Larriba, A Insa, M Provencio, A Torres, D Isla, ...
Journal of clinical oncology 25 (30), 4736-4742, 2007
|Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and BiomarkersT-DM1 in HER2 …|
S Peters, R Stahel, L Bubendorf, P Bonomi, A Villegas, DM Kowalski, ...
Clinical Cancer Research 25 (1), 64-72, 2019
|Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy|
M Nogué‐Aliguer, J Carles, A Arrivi, O Juan, L Alonso, A Font, B Mellado, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
|Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study|
M Gonzalez-Baron, J Feliu, I De la Gandara, E Espinosa, A Colmenarejo, ...
European Journal of Cancer 31 (13-14), 2215-2219, 1995
|New molecular targeted therapies integrated with radiation therapy in lung cancer|
M Provencio, A Sánchez, P Garrido, F Valcárcel
Clinical lung cancer 11 (2), 91-97, 2010
|Phase III trial comparing vinflunine with docetaxel in second-line advanced non–small-cell lung cancer previously treated with platinum-containing chemotherapy|
M Krzakowski, R Ramlau, J Jassem, A Szczesna, P Zatloukal, ...
Journal of Clinical Oncology 28 (13), 2167-2173, 2010